pathogenesi
immun
respons
middl
east
respiratori
syndrom
mer
caus
recent
discov
coronaviru
merscov
fulli
character
part
suitabl
anim
model
mimic
human
mer
current
avail
nonhuman
primat
nhp
rhesu
monkey
macaca
mulatta
common
marmoset
callithrix
jacchu
inocul
merscov
via
combin
intratrach
intranas
oral
ocular
rout
develop
transient
respiratori
diseas
littl
viremia
although
lethal
diseas
observ
small
number
marmoset
fdg
petct
realtim
noninvas
approach
benefici
provid
biomark
host
immun
respons
diseas
progress
fdgpetct
use
track
host
immun
respons
monkeypox
viru
human
immunodefici
infect
fdg
uptak
increas
activ
macrophag
lymphocyt
granulocyt
inflamm
immun
respons
local
pet
imag
track
host
respons
noninvas
especi
use
anim
speci
studi
limit
andor
expens
obtain
anim
develop
overt
clinic
sign
diseas
appli
fdgpetct
imag
monitor
infect
develop
rhesu
macaqu
merscov
inhal
compar
standard
uptak
valu
suv
increas
accuraci
measur
fdg
uptak
appli
kinet
model
patlak
graphic
analysi
assess
net
fdg
uptak
rate
constant
ki
primari
lymphoid
tissu
engag
host
respons
merscov
exposur
studi
first
applic
methodolog
acut
infecti
diseas
process
rhesu
macaqu
hous
biosafeti
level
contain
facil
accredit
associ
assess
accredit
laboratori
anim
care
intern
experiment
procedur
approv
nation
institut
allergi
infecti
diseas
niaid
divis
clinic
research
dcr
anim
care
use
committe
complianc
anim
welfar
act
regul
public
health
servic
polici
guid
care
use
laboratori
anim
recommend
aerosol
inhal
strain
genbank
access
grown
eagl
minimum
essenti
medium
lonza
md
usa
vero
cell
prior
aerosol
challeng
four
rhesu
macaqu
two
male
two
femal
year
old
weigh
kg
anesthet
intramuscular
ketamin
mgkg
inject
headout
plethysmographi
buxcodata
scienc
intern
mn
usa
use
calcul
averag
respiratori
minut
volum
mlmin
multipli
respir
rate
tidal
volum
aerosol
concentr
deriv
skc
biosampl
skc
inc
pa
usa
use
calcul
present
dose
within
negativepressur
pa
headonli
aerosol
exposur
chamber
macaqu
expos
smallparticl
aerodynam
diamet
target
lung
alveoli
aerosol
challeng
inhal
dose
plaqueform
unit
imag
data
acquir
gemini
petct
clinic
scanner
philip
healthcar
andov
usa
axial
fieldofview
fov
mm
pet
scanner
entir
nhp
thorax
imag
singl
bed
posit
use
scanner
brain
protocol
result
transvers
field
view
mm
led
cubic
voxel
reconstruct
imag
lowdos
ct
imag
thorax
pet
attenu
purpos
acquir
kvp
slice
thick
space
contrast
given
subject
freeli
breath
scan
pet
imag
acquisit
initi
immedi
lowdos
ct
scan
min
prior
intraven
inject
fdg
mbqkg
saphen
vein
continu
min
nine
imag
session
per
anim
conduct
preinocul
day
postinocul
day
merscov
suv
pet
imag
reconstruct
iter
use
manufactur
suppli
lineofrespons
lor
base
rowact
maximumlikelihood
algorithm
method
scatter
decay
random
attenu
correct
appli
imag
reconstruct
process
scatter
attenu
correct
base
lowdos
ct
imag
acquir
prior
pet
scan
list
mode
data
sort
dynam
frame
creation
histogram
extract
earli
tracer
dynam
distribut
arteri
blood
initi
data
set
min
compris
frame
follow
time
sequenc
frame
frame
frame
frame
frame
frame
sequenc
follow
frame
frame
captur
late
slow
phase
dynam
distribut
tracer
blood
tissu
pet
imag
reconstruct
iter
use
orderedsubset
expectationmaxim
algorithm
two
iter
nine
subset
follow
iter
maximum
posteriori
reconstruct
maximum
posteriori
paramet
adjust
provid
uniform
spatial
resolut
mm
fullwidth
halfmaximum
mm
three
direct
method
scatter
decay
random
attenu
correct
appli
process
pet
imag
reconstruct
reconstruct
suv
pet
imag
analyz
without
postreconstruct
smooth
use
pmod
version
pmod
technolog
zurich
ch
extract
imagederiv
input
function
idif
voi
sphere
place
left
ventricl
arch
aorta
use
frame
first
min
fdg
inject
fig
b
averag
data
two
voi
use
gener
idif
fig
twoml
sphere
place
axillari
mediastin
ln
lumbar
spine
bone
marrow
describ
previous
sphere
place
right
left
side
lung
obtain
tissu
time
activ
curv
tac
last
time
point
tac
use
gener
suv
data
use
standard
twotissu
compart
kinet
model
irrevers
tracer
metabol
fig
tracer
influx
constant
ki
comput
lymphoid
lung
tissu
blood
volum
fraction
vb
includ
model
patlak
linear
regress
method
appli
paramet
estim
util
idif
fdg
tissu
tac
pmod
version
pmod
technolog
tissu
tac
fit
model
use
nonlinear
leastsquar
method
levenbergmarquardt
algorithm
minim
weight
sum
squar
error
pet
measur
model
solut
plot
ratio
cti
cbl
ratio
cumul
instantan
blood
activ
concentr
normal
time
becam
linear
late
phase
tracer
inject
concentr
free
ie
unmetabol
fdg
blood
equilibr
free
tracer
extravascular
volum
distribut
linear
part
plot
fit
eq
identifi
ki
slope
regress
minim
usepackag
amsmath
usepackag
wasysym
usepackag
amsfont
usepackag
amssymb
usepackag
amsbsi
usepackag
mathrsf
usepackag
upgreek
setlength
oddsidemargin
begin
document
frac
c
mathrm
ti
c
mathrm
bl
k
ifrac
displaystyl
underset
overset
int
c
mathrm
bl
c
mathrm
bl
v
mathrm
dist
end
document
cti
cbl
repres
radioact
concentr
region
interest
arteri
blood
assess
pet
imag
differ
time
point
fdg
inject
respect
vdist
initi
distribut
volum
criterion
maximum
error
set
deriv
model
paramet
valu
fdg
model
describ
fig
slope
equal
complet
blood
cell
count
determin
petscan
day
bodi
temperatur
bodi
weight
monitor
daili
everi
day
respect
twoway
repeat
measur
analysi
varianc
anova
post
hoc
bonferroni
multipl
comparison
test
use
ki
obtain
preinocul
postinocul
merscov
voi
locat
independ
variabl
character
host
immun
respons
twoway
repeat
measur
anova
use
ki
differ
time
point
preinocul
merscov
voi
locat
within
two
factor
respect
correl
ki
valu
mediastin
axillari
ln
bone
marrow
monocyt
fraction
blood
mediastin
axillari
ln
calcul
use
pearson
product
moment
correl
coeffici
r
agostino
pearson
test
appli
confirm
data
follow
gaussian
distribut
graphpad
prizm
graphpad
softwar
inc
la
jolla
ca
usa
use
statist
analys
analysi
lung
data
reveal
patholog
ct
imag
chang
fdg
uptak
day
merscov
inhal
data
shown
chang
bodi
temperatur
bodi
weight
blood
glucos
concentr
mgdl
prior
exposur
mgdl
exposur
observ
howev
fdg
uptak
indic
suv
increas
mediastin
axillari
ln
postinhal
fig
addit
file
movi
analysi
complet
blood
cell
count
reveal
slight
increas
within
normal
rang
circul
monocyt
peak
day
postinhal
remain
elev
remaind
studi
fig
imag
first
time
frame
compris
caught
fast
kinet
fdg
distribut
arteri
blood
fig
rest
six
time
frame
min
durat
cover
slow
distribut
accumul
fdg
tissu
later
time
point
min
slow
phase
addit
file
movi
fig
suv
tac
axillari
ln
plateau
min
fdg
inject
similar
throughout
studi
durat
month
fig
analog
bone
marrow
suv
tac
show
signific
variat
studi
howev
compar
axillari
ln
tac
bone
marrow
continu
rise
min
fdg
inject
fig
c
suggest
longer
time
fdg
inject
tissu
high
cell
glycolyt
activ
reach
steadi
state
mediastin
ln
tac
rise
pronounc
day
postinhal
indic
tac
fig
repres
patlak
plot
bone
marrow
mediastin
axillari
ln
shown
fig
ki
obtain
day
prior
viru
exposur
remain
unchang
lymphoid
tissu
fig
b
mean
baselin
ki
prior
merscov
exposur
similar
axillari
mediastin
ln
sd
sd
respect
greater
elev
mean
ki
valu
almost
sixfold
increas
preexposur
scan
mediastin
ln
observ
within
first
week
merscov
exposur
compar
mean
ki
valu
twofold
increas
preexposur
scan
axillari
ln
sd
sd
mediastin
axillari
ln
day
postexposur
respect
fig
b
e
fdg
mean
ki
bone
marrow
prior
merscov
exposur
fivefold
higher
sd
compar
observ
ln
follow
pattern
ln
chang
observ
viru
challeng
fig
statist
analysi
use
twoway
repeat
measur
anova
reveal
alter
ki
valu
associ
time
point
p
viru
exposur
locat
lymphoid
tissu
p
reveal
statist
signific
interact
p
two
factor
pattern
chang
ki
time
differ
three
locat
subject
post
hoc
analysi
bonferroni
multipl
comparison
test
specifi
statist
signific
increas
ki
mediastin
ln
postexposur
compar
ki
valu
prior
viru
challeng
p
fig
correl
ki
chang
axillari
mediastin
ln
statist
signific
r
p
data
shown
addit
chang
fdg
uptak
indic
ki
mediastin
axillari
ln
correl
elev
percentag
monocyt
peripher
blood
r
p
r
p
respect
fig
comparison
result
obtain
ki
evalu
host
respons
merscov
exposur
use
suv
min
fdg
inject
addit
file
fig
last
time
point
tac
fig
b
main
differ
find
use
ki
suv
correl
chang
mediastin
axillari
ln
data
shown
monocyt
fraction
suv
axillari
ln
lost
addit
file
fig
addit
first
pronounc
increas
fdg
uptak
axillari
ln
observ
day
postexposur
ki
fig
detect
analyz
suv
fig
furthermor
magnitud
chang
axillari
ln
associ
viru
exposur
greater
ki
compar
suv
fig
f
exampl
averag
percent
chang
ki
axillari
ln
sd
increas
fdg
uptak
merscov
exposur
determin
suv
twofold
less
sd
monitor
uptak
primarili
lymphoid
tissu
differ
locat
respons
aerosol
merscov
challeng
nhp
group
mediastin
ln
show
specif
pattern
chang
ki
day
postviru
exposur
correl
ki
chang
axillari
lymph
node
mediastin
ln
lungdrain
ln
ln
greatest
increas
ki
valu
compar
lymphoid
tissu
increas
ki
axillari
ln
observ
mediastin
ln
statist
signific
nevertheless
chang
ki
axillari
mediastin
ln
concurr
elev
percentag
monocyt
peripher
blood
shown
previous
publish
studi
ln
activ
viral
infect
gener
fdg
signal
easili
discern
background
activ
activ
lymphocyt
increas
glucos
uptak
approxim
h
moreov
result
longitudin
studi
rhesu
macaqu
challeng
simianhuman
immunodefici
viru
human
withdraw
antiretrovir
therapi
indic
increas
ln
tissu
fdg
uptak
preced
fulmin
viru
replic
system
factor
viral
protein
cytokin
could
engag
lymphoid
tissu
respons
monocyt
part
immun
respons
viru
infect
eg
cytokin
releas
phagocytosi
correl
increas
monocyt
fraction
fdg
uptak
ln
surpris
compar
kinet
model
use
ki
analysi
use
suv
quantifi
fdg
uptak
definit
suv
repres
radioact
concentr
region
interest
adjust
inject
dose
bodi
weight
therefor
suv
influenc
sever
paramet
bodi
composit
blood
glucos
concentr
time
interv
fdg
inject
imag
acquisit
note
tac
bone
marrow
throughout
studi
mediastin
ln
day
postexposur
suv
reach
plateau
within
min
fdg
inject
thu
high
metabol
activ
prolifer
cell
bone
marrow
requir
longer
time
fdg
reach
steadi
state
tissu
even
physiolog
condit
ln
biopsi
perform
current
studi
futur
studi
sampl
tissu
mediastin
ln
peak
respons
abl
identifi
specif
cell
type
associ
increas
fdg
uptak
ln
notabl
appli
kinet
model
analysi
abl
determin
steadi
state
paramet
character
system
base
two
process
fdg
deliveri
blood
tissu
interest
state
cell
metabol
activ
multipl
time
point
petacquir
data
use
kinet
model
analysi
accuraci
ki
comput
small
region
interest
higher
compar
suv
even
presenc
high
nois
studi
kinet
model
increas
signaltonois
ratio
result
improv
accuraci
measur
method
sensit
analysi
suv
effect
mild
semiquantit
analysi
suv
abl
detect
studi
attempt
develop
aerosol
nhp
model
merscov
infect
current
nhp
aerosol
model
fail
caus
overt
sign
merscov
infect
comparison
result
merscov
challeng
studi
rhesu
macaqu
hamper
differ
dose
unit
rout
administr
dose
given
previou
studi
express
tissu
cultur
infecti
dose
given
combin
intratrach
ocular
oral
intranas
rout
intratrach
rout
nevertheless
fdgpet
quantit
host
respons
viru
challeng
ct
reveal
patholog
imag
sensit
ct
detect
host
respons
lower
fdgpet
similarli
result
merscov
exposur
rabbit
demonstr
merscov
replic
lung
tissu
without
develop
overt
clinic
sign
subclin
merscov
infect
report
often
patient
without
comorbid
patient
comorbid
anim
model
use
studi
host
respons
merscov
test
intervent
strategi
aim
inhibit
merscov
replic
howev
suppress
immun
respons
merscov
exposur
anim
may
need
reflect
sever
mer
observ
major
patient
limit
feasibl
studi
small
number
subject
preexist
health
statu
studi
use
young
previous
healthi
anim
appar
intact
immun
respons
translat
find
older
mer
patient
numer
comorbid
done
caution
sinc
fdgpet
identifi
locat
pattern
host
respons
viru
challeng
futur
studi
higher
challeng
dose
investig
chang
fdg
uptak
along
result
histopatholog
immunolog
analysi
respons
lymphoid
tissu
fdg
gener
consid
nonspecif
tracer
inflammationimmun
activ
cell
involv
host
respons
specifi
fdgpet
howev
depend
viru
diseas
stage
certain
popul
immun
cell
involv
respons
therefor
locat
pattern
fdg
chang
bodi
infect
progress
viru
specif
compar
clinic
applic
fdgpet
mostli
use
diagnost
purpos
preclin
studi
perform
control
condit
use
within
subject
design
metabol
map
bodi
determin
prior
viru
exposur
use
identifi
locat
tissu
elev
glycolyt
activ
exposur
specif
pattern
fdg
chang
foci
identifi
pet
pre
postexposur
state
monitor
daybyday
pattern
locat
fdg
chang
identifi
follow
viru
exposur
pattern
use
monitor
effect
treatment
previou
studi
describ
host
respons
monkeypox
viru
show
pattern
locat
fdg
chang
lymphoid
tissu
distinct
observ
merscov
exposur
addit
abl
describ
differ
surviv
nonsurviv
anim
detect
earli
stage
monkeypox
infect
ongo
studi
analysi
biopsi
tissu
sampl
locat
identifi
pet
abl
shed
light
specif
mechan
associ
fdg
chang
viru
exposur
rhesu
macaqu
hous
biosafeti
level
contain
facil
accredit
associ
assess
accredit
laboratori
anim
care
intern
experiment
procedur
approv
nation
institut
allergi
infecti
diseas
niaid
divis
clinic
research
dcr
anim
care
use
committe
complianc
anim
welfar
act
regul
public
health
servic
polici
guid
care
use
laboratori
anim
recommend
